{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"5.8","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"TTR is defined as the time from first dose of any study drug treatment to the date of first documentation of PR or better. PR is defined as \\>=50% reduction of serum M protein and reduction in 24-hour urinary M protein by \\>=90%/to \\<200 mg/24 hours; In addition, if present at baseline, \\>=50% reduction in size of soft tissue plasmacytomas; no known evidence of progressive/new bone lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib, 4 mg, capsules, orally, on Days 1, 8 and 15 of each 28-day cycle along with daratumumab, 16 mg/kg, intravenously (IV), on Days 1, 8, 15 and 22 of Cycles 1 and 2, on Days 1 and 15 (every 2 weeks) for Cycles 3 to 6 and on Day 1 (every 4 weeks) for Cycle 7 and beyond along with dexamethasone, 20 mg, tablets, orally on Days 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day cycle until progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or up to 5 years.","id":"OG000","title":"Ixazomib 4 mg + Daratumumab 16 mg/kg + Dexamethasone 20 mg"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable population included participants who received at least 1 dose of ixazomib, had measurable disease during the screening period, and had at least 1 postbaseline disease assessment.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Time To Response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}